Compare TRX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | ENTA |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.1M | 378.0M |
| IPO Year | 2002 | 2012 |
| Metric | TRX | ENTA |
|---|---|---|
| Price | $1.18 | $13.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.70 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 2.9M | 204.2K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $84.84 | $7.76 |
| Revenue Next Year | $96.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $0.51 | $7.05 |
| 52 Week High | $2.80 | $17.15 |
| Indicator | TRX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 45.89 |
| Support Level | $1.06 | $12.48 |
| Resistance Level | $1.27 | $13.98 |
| Average True Range (ATR) | 0.06 | 0.62 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 52.63 | 18.47 |
TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.